Be the first person to write a business review for Access Pharmaceuticals, Inc.

Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania. Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company’s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals, Inc. (Aeolus) is a pharmaceutical company engaged in development of medical countermeasures against biological, chemical and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The Company is testing its lead compound, AEOL 10150, in a range of indications each in various stages of development. The Company’s lead indications are a medical countermeasure against the effects of acute radiation syndrome (ARS) in the lungs and in the gastro-intestinal tract, and a medical countermeasure against the effects of sulfur mustard gas and chlorine gas. The Company is also developing its second drug candidate AEOL 11207 for the treatment of epilepsy and Parkinson’s disease.

Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers.Alexion Pharmaceuticals drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors.

Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California. Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches.Alexza products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company's single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.

Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California. Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment offers a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, and allergy; Botox for the therapeutic and aesthetic indications; skin care products for acne, psoriasis, and other skin care products; eyelash growth products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the Lap-Band System and the BIB BioEnterics Intragastric Balloon; and facial aesthetics products.Allergan company also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, and ambulatory surgery centers, as well as to medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A.; Spectrum Pharmaceuticals, Inc.; and Pieris AG.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.